Skip to content
    LSP (EQT Life Sciences) logo

    LSP (EQT Life Sciences)

    Amsterdam, NetherlandsFounded 1987
    eqtgroup.com/en/private-capital/eqt-life-sciencesLinkedIn
    Biotech & Life SciencesHealthcare

    EQT Life Sciences (formerly LSP / Life Sciences Partners) is one of Europe's largest and most experienced life sciences venture capital firms, investing in innovative companies focused on therapeutics, medical devices, diagnostics, and healthtech. Founded in 1987 and headquartered in Amsterdam, it was acquired by EQT in March 2022 and renamed EQT Life Sciences.

    44% of their portfolio is in Biotech & Life Sciences. Average disclosed round size is $81.9M (across 89 rounds with reported amounts).

    Find people at LSP (EQT Life Sciences) on Goldilocks AI

    Portfolio

    103

    Fund Size

    $1.1B

    Top Stage

    Series B

    Last 12 Mo

    17

    Team

    PF

    Per Franzén

    CEO and Managing Partner

    BJ

    Bert Janssens

    Partner, Co-Head of Private Capital

    HS

    Henry Steinberg

    Partner, Global Head of EQT Real Estate

    JY

    James Yu

    Partner, Head of Global Client Solutions

    MH

    Masoud Homayoun

    Partner, Head of EQT Infrastructure

    JC

    Jeremy Coller

    Head and Chief Investment Officer of Coller EQT

    AE

    Alexandra Edlund

    Chief People Officer

    CD

    Christina Drews

    Chief Operating Officer

    GS

    Gustav Segerberg

    Chief Financial Officer

    RF

    Roberta Ferrari

    Managing Director

    CB

    Christoph Broja

    Partner

    AR

    Abhiram Rao

    Director

    Portfolio Breakdown

    Stage Distribution

    Sector Distribution

    Investment Activity

    DealsAvg Round Size

    Portfolio

    151 investments
    CompanyRoundAmountDate
    Vaderis Therapeutics logoVaderis TherapeuticsUnknown$152MOct 2026
    AAgomabSeries A$100MSep 2026
    Agomab Therapeutics logoAgomab TherapeuticsSeries D$89MSep 2026
    Vaderis Therapeutics logoVaderis TherapeuticsSeries B$152.5MAug 2026
    RQ Biotechnology logoRQ BiotechnologySeries A$115MJun 2026
    Neurent Medical logoNeurent MedicalSeries C$74MFeb 2026
    Aerska logoAerskaSeries A$39MFeb 2026
    Tenpoint Therapeutics logoTenpoint TherapeuticsSeries B—Jan 2026
    Exciva logoExcivaSeries B—Jan 2026
    Kinaset Therapeutics logoKinaset TherapeuticsSeries B$103MJan 2026
    KKinasetSeries B$103MJan 2026
    RQ Biotechnology logoRQ BiotechnologySeries A$115MJan 2026
    FoRx Therapeutics logoFoRx TherapeuticsSeries A$50MDec 2025
    Xeltis logoXeltisGrowth—Dec 2025
    Artios logoArtiosSeries D$115MNov 2025
    Electra logoElectraSeries C$183MOct 2025
    EElectra TherapeuticsSeries C$183MOct 2025
    Tubulis logoTubulisSeries C—Oct 2025
    TTubulis GmbHSeries C—Oct 2025
    ViCentra logoViCentraSeries D$85MSep 2025
    CCyted HealthSeries B$44MSep 2025
    Cyted logoCytedSeries B$44MSep 2025
    Neuros Medical logoNeuros MedicalSeries D$56MJul 2025
    Neuros logoNeurosSeries D$56MJul 2025
    SpliceBio logoSpliceBioSeries B$135MJun 2025
    Page 1 of 7

    Top Co-Investors

    Andera Partners28 shared
    Sofinnova Partners17 shared
    Gimv15 shared
    Kurma Partners13 shared
    OrbiMed13 shared
    Forbion12 shared
    Novartis Venture Fund11 shared
    Pfizer Ventures11 shared
    Omega Funds11 shared
    RA Capital Management11 shared
    The Invus Group, LLC10 shared
    Sanofi Ventures10 shared
    Sectoral Asset Management10 shared
    Bpifrance9 shared
    M Ventures9 shared
    Novartis Pharma AG8 shared
    Pontifax8 shared
    Fountain Healthcare Partners8 shared
    Fidelity Management & Research Company8 shared
    Wellington Management8 shared

    Last updated: 20 October 2026